Ionis Pharmaceuticals, Inc.
Modulators of PCSK9 expression
Last updated:
Abstract:
The present embodiments provide methods, compounds, and compositions useful for inhibiting PCSK9 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PCSK9.
Status:
Grant
Type:
Utility
Filling date:
1 Nov 2019
Issue date:
11 May 2021